UBE2T and breast carcinoma: Similarly, in lung adenocarcinoma (LUAD) [55], breast cancer (BCa) [56], renal cell carcinoma (RCC) [57], and osteosarcoma [58], the downregulation of UBE2T has been found to inhibit PI3K/AKT signaling activity and suppress cancer progression.